Pacific Biosciences of California (PACB) PT Lowered to $15 at TD Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall St set for steady open as oil jumps ahead of key earnings
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's Russian supply announcements
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- Iren shares jump 5% in premarket trade on report of Anthropic AI cloud deal
Tweet
Share
E-mailGet Alerts PACB Hot Sheet
Price: $2.33 --0%
Rating Summary:
9 Buy, 11 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 20 | New: 46
Rating Summary:
9 Buy, 11 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 20 | New: 46
Join SI Premium – FREE
TD Cowen analyst Dan Brennan lowered the price target on Pacific Biosciences of California (NASDAQ: PACB) to $15.00 (from $19.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Ford (F) PT Lowered to $16 at JPMorgan Into Q3 Earnings
- Western Digital Corp. (WDC) PT Lowered to $470 at UBS
- Increasing unusual option volume: ABUS PACB DNA GMAB TWST HHH
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
